Besunyen Holdings Co Ltd

Besunyen Holdings maintains a strong liquidity position, with a current ratio of 2.98 and cash and equivalents of CNY 177.9 million, representing 31.6% of total assets. The company's price-to-book ratio of 0.63 and price-to-tangible-book ratio of 0.63 suggest a discount to net asset value, while the debt-to-equity ratio of 0.01 indicates minimal leverage. The low liquidity risk is supported by the absence of immediate filing-based liquidity flags. Profitability metrics show Besunyen's return on equity (ROE) of 4.37% and return on assets (ROA) of 3.63% lag behind the Food Processing industry's median ROE of 8.2% and ROA of 5.1%. Gross margin of 70.1% (CNY 346.6 million gross profit on CNY 494.3 million revenue) is in line with the industry median of 68.5%, but operating margin of 5.6% (CNY 27.5 million operating income) is below the 7.3% median, indicating inefficiencies in cost control. The company's revenue is concentrated in the domestic market, with no disclosed international operations. Segment-wise, the Tea Products segment drives the majority of revenue, though the Weight-Loss and Other Medicines segment contributes a significant portion. No specific revenue percentages by segment are disclosed, but the product portfolio suggests a focus on health and wellness. Growth trajectory is mixed. Revenue of CNY 494.3 million in the latest period shows a 12.3% year-over-year increase, but net income of CNY 20.4 million reflects a 15.6% decline. The company's outlook for the current fiscal year (FY) projects a 6.8% revenue increase and a 9.2% improvement in net income, while the next FY forecasts a 4.1% revenue decline and a 12.4% net income contraction. These projections suggest a slowdown in momentum. Risk assessment indicates low dilution and liquidity risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position reduce financial leverage risk. However, the low ROE and ROA suggest operational inefficiencies that could pressure margins in a competitive market. No dilution sources were identified in filings, and the dilution near-term probability is assessed as low. Recent events include the release of the latest financial snapshot, which shows a 12.3% revenue increase but a 15.6% net income decline. No material events were disclosed in filings or transcripts in the past 90 days. The company's product portfolio remains focused on therapeutic tea and weight-loss medicines, with no new product launches or strategic shifts reported.